Literature DB >> 21150275

CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation.

Vivian Chen1, Emma Shtivelman.   

Abstract

CC3/TIP30 is a metastasis and tumor suppressor, with reduced or absent expression in a variety of aggressive tumors. Overexpression of CC3 in tumor cells predisposes them to apoptosis in response to different death signals. We found that silencing of CC3 expression does not increase apoptotic resistance of cells. However, it strongly improves survival of tumor cells in response to glucose limitation. HeLa cells with silenced CC3 survive long-term in low glucose, and, in comparison to control HeLa cells, show superior metabolic adaptation to glucose limitation. First, unlike the parental HeLa cells, HeLa with silenced CC3 activate and maintain high levels of mitochondrial respiration that is critical for their ability to thrive in low glucose. Second, silencing of CC3 leads to higher expression levels of mitochondrial proteins in respiration complexes when cells are continuously cultured in limiting glucose. Third, HeLa cells with silenced CC3 maintain higher levels of c-MYC and the M2 isoform of pyruvate kinase in low glucose, contributing to more efficient glycolysis. Fourth, HeLa cells with silenced CC3 fail to fully activate AMPK in response to glucose limitation. Inhibition of AMPK, either pharmacologic or via siRNA, protects control HeLa cells from death in low glucose. The metabolic flexibility acquired by cells after silencing of CC3 could be directly relevant to the development of metastatic and aggressive human tumors that frequently have low or absent expression of CC3.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21150275      PMCID: PMC3047816          DOI: 10.4161/cc.9.24.14230

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  61 in total

Review 1.  AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.

Authors:  Zhijun Luo; Mengwei Zang; Wen Guo
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

2.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

Review 3.  Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer.

Authors:  S Fogarty; D G Hardie
Journal:  Biochim Biophys Acta       Date:  2009-09-22

Review 4.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer.

Authors:  R J DeBerardinis; T Cheng
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

5.  PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis.

Authors:  Nabil Djouder; Roland D Tuerk; Marianne Suter; Paolo Salvioni; Ramon F Thali; Roland Scholz; Kari Vaahtomeri; Yolanda Auchli; Helene Rechsteiner; René A Brunisholz; Benoit Viollet; Tomi P Mäkelä; Theo Wallimann; Dietbert Neumann; Wilhelm Krek
Journal:  EMBO J       Date:  2009-11-26       Impact factor: 11.598

Review 6.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

7.  Decreased TIP30 expression promotes tumor metastasis in lung cancer.

Authors:  Xin Tong; Kai Li; Zhigang Luo; Bin Lu; Xing Liu; Tao Wang; Mingshu Pang; Beibei Liang; Min Tan; Mengchao Wu; Jian Zhao; Yajun Guo
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

Review 8.  LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism.

Authors:  Marnix Jansen; Jean Paul Ten Klooster; G Johan Offerhaus; Hans Clevers
Journal:  Physiol Rev       Date:  2009-07       Impact factor: 37.312

Review 9.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

10.  p32 (C1QBP) and cancer cell metabolism: is the Warburg effect a lot of hot air?

Authors:  Chi V Dang
Journal:  Mol Cell Biol       Date:  2010-01-25       Impact factor: 4.272

View more
  20 in total

1.  Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics.

Authors:  Ubaldo E Martinez-Outschoorn; Marco Prisco; Adam Ertel; Aristotelis Tsirigos; Zhao Lin; Stephanos Pavlides; Chengwang Wang; Neal Flomenberg; Erik S Knudsen; Anthony Howell; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

2.  Release the ink4a/arf growth suppression by "u" and "me"?

Authors:  Shuo Qie; Nianli Sang
Journal:  Cell Cycle       Date:  2011-01-15       Impact factor: 4.534

Review 3.  Novel therapeutic targets of tumor metabolism.

Authors:  Rigel J Kishton; Jeffrey C Rathmell
Journal:  Cancer J       Date:  2015 Mar-Apr       Impact factor: 3.360

4.  Metabolic imaging: a link between lactate dehydrogenase A, lactate, and tumor phenotype.

Authors:  Inna Serganova; Asif Rizwan; Xiaohui Ni; Sunitha B Thakur; Jelena Vider; James Russell; Ronald Blasberg; Jason A Koutcher
Journal:  Clin Cancer Res       Date:  2011-08-15       Impact factor: 12.531

5.  Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Authors:  William H Chappell; Stephen L Abrams; Richard A Franklin; Michelle M LaHair; Giuseppe Montalto; Melchiorre Cervello; Alberto M Martelli; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Jerry Polesel; Renato Talamini; Michele Milella; Agostino Tafuri; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

6.  TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice.

Authors:  A Li; C Zhang; S Gao; F Chen; C Yang; R Luo; H Xiao
Journal:  Oncogene       Date:  2012-06-25       Impact factor: 9.867

7.  Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.

Authors:  Zhigui Guo; Manqing Cao; Abin You; Junrong Gao; Hongyuan Zhou; Huikai Li; Yunlong Cui; Feng Fang; Wei Zhang; Tianqiang Song; Qiang Li; Xiaolin Zhu; Huichuan Sun; Ti Zhang
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

Review 8.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

9.  Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling.

Authors:  Lilia Alberghina; Daniela Gaglio; Cecilia Gelfi; Rosa M Moresco; Giancarlo Mauri; Paola Bertolazzi; Cristina Messa; Maria C Gilardi; Ferdinando Chiaradonna; Marco Vanoni
Journal:  Front Physiol       Date:  2012-09-12       Impact factor: 4.566

10.  The P2X7 receptor is a key modulator of aerobic glycolysis.

Authors:  F Amoroso; S Falzoni; E Adinolfi; D Ferrari; F Di Virgilio
Journal:  Cell Death Dis       Date:  2012-08-16       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.